References
- Cunha BA. Clinical relevance of penicillin-resistant Streptococcus pneumoniae. Semin Respir Infect 2002; 17(3): 204–14
- Harwell JI, Brown RB. The drug-resistant pneumococcus: clinical relevance, therapy, and prevention. Chest 2000; 117(2): 530–41
- Pihlajamski M, Kotilainen P, Kaurila T, et al. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001;33(4): 483–8
- Shea KW, Cunha BA, Ueno Y, et al. Doxycycline activity against Streptococcus pneumoniae. (Letter) Chest 1995;108(6): 1775–6
- Miisher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to heta-lactatn antibiotics. Arch Intern Med 2001; 161 (21):2538–44
- Brueggemann AB, Pfaller MA, Doern GV. Use of penicillin MICs to predict in vitro activity of other beta-lactam antimicrobial agents against Streptococcus pneumoniae. J Clin Microbiol 2001;39(1): 367–9
- Quintiliani R, Nicolau DP, Nightingale CH. Clinical relevance of penicillin-resistant Streptococcus pneumoniae, with particular attention to therapy with ceftizoxime, cefotaxime, and ceftriaxone. Infect Dis Clin Pract 1996; 5(1 Suppl):S37–41
- Cunha BA. Community-acquired pneumonia: diagnostic and therapeutic approach. Med Clin North Am 2001;85(1): 43–77
- Cunha BA. Ciprofloxacin resistant Streptococcus pneumoniae, not fluoroquinolone resistant Streptococcus pneumoniae. Infect Dis Pract 2000;24:30–1
- Garcia-Rey C, Aguilar L, Baquero F, et al. Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. (Letter) Antimicrob Agents Chemother 2000;44(12): 3481–2
- Cunha BA. Effective antibiotic-resistance control strategies. (Editorial) Lancet 2001;357:1307–8